3rd Dry AMD Therapeutics Summit
Evvnt Promotion / evvnt
30.11.2022 - 02.12.2022 Revere Hotel Boston Common, 200 Stuart Street, 02116 Boston, Massachusetts, USA
Time: 07:50 - 12:00
Kongressthemen
2022 hosts the race between IVERIC Bio and Apellis for regulatory approval of the very first marketable dry AMD treatment. In addition to clinical advances, the field will see plenty of technology advances for more patient-compliant therapeutics, with the favourable one-dose gene therapy approach addition to pipelines, and optimized biomarker technology.
Join our 30+ expert speakers as we tackle the most critical roadblocks preventing your drugs getting the patients who need them.
2022 hosts the race between IVERIC Bio and Apellis for regulatory approval of the very first marketable dry AMD treatment. In addition to clinical advances, the field will see plenty of technology advances for more patient-compliant therapeutics, with the favourable one-dose gene therapy approach addition to pipelines, and optimized biomarker technology.
Join our 30+ expert speakers as we tackle the most critical roadblocks preventing your drugs getting the patients who need them.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anmerkungen
Brochure: https://go.evvnt.com/1279770-3?pid=4832
Speakers: Abraham Scaria | Chief Scientific Officer | AGTC, Anneke Der Hollander | Senior Principal Scientist and Ophthalmology Lead | AbbVie, and more.
Brochure: https://go.evvnt.com/1279770-3?pid=4832
Speakers: Abraham Scaria | Chief Scientific Officer | AGTC, Anneke Der Hollander | Senior Principal Scientist and Ophthalmology Lead | AbbVie, and more.
Anfragen und Anmeldung:
https://go.evvnt.com/1279770-2?pid=4832
Frau Stephanie Nketia
Allgemeinmedizin
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
